UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

Biochemical Society transactions, 2016-06, Vol.44 (3), p.951

2016

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Haematologica (Roma), 2021-02, Vol.106 (2), p.585-588

2021

Link zum Volltext

Verfügbarkeit prüfen

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

Frontiers in immunology, 2016-12, Vol.7, p.648-648

2016

Link zum Volltext

Verfügbarkeit prüfen

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Link zum Volltext

Verfügbarkeit prüfen

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Clinical immunology (Orlando, Fla.), 2016-08, Vol.169, p.107-113

2016

Link zum Volltext

Verfügbarkeit prüfen

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Frontiers in immunology, 2018-09, Vol.9, p.2034-2034

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Molecular therapy, 2013-04, Vol.21 (4), p.904-912

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Cytotherapy (Oxford, England), 2013-05, Vol.15 (5), p.620-626

2013

Link zum Volltext

Verfügbarkeit prüfen

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

Blood, 2011-01, Vol.117 (1), p.72-82

2011

Link zum Volltext

Verfügbarkeit prüfen

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Clinical cancer research, 2017-10, Vol.23 (20), p.6012-6020

2017

Link zum Volltext

Verfügbarkeit prüfen

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

Clinical cancer research, 2022-04, Vol.28 (8), p.1572-1585

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Journal of clinical oncology, 2006-05, Vol.24 (13), p.e20-e22

2006

Link zum Volltext

Verfügbarkeit prüfen

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Clinical cancer research, 2010-12, Vol.16 (23), p.5852-5861

2010

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Blood, 2016-10, Vol.128 (17), p.2165-2174

2016

Link zum Volltext

Verfügbarkeit prüfen

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Clinical cancer research, 2014-09, Vol.20 (18), p.4776-4783

2014

Link zum Volltext

Verfügbarkeit prüfen

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

Cancer Immunology, Immunotherapy, 2007-12, Vol.56 (12), p.1875-1883

2007

Link zum Volltext

Verfügbarkeit prüfen

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Blood, 2001-09, Vol.98 (5), p.1358-1364

2001

Link zum Volltext

Verfügbarkeit prüfen

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001607

2020

Link zum Volltext

Verfügbarkeit prüfen

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

Human gene therapy. Part B. Methods, 2014-12, Vol.25 (6), p.345

2014

Link zum Volltext

Verfügbarkeit prüfen

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

Thrombosis and haemostasis, 2010-08, Vol.104 (2), p.318

2010

Link zum Volltext

Verfügbarkeit prüfen

Quantification of circulating endothelial cells by flow cytometry

Clinical cancer research, 2009-05, Vol.15 (10), p.3640; author reply 3640-3640

2009

Link zum Volltext

Verfügbarkeit prüfen

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.841-848

2012

Link zum Volltext

Verfügbarkeit prüfen

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors

Journal of immunotherapy (1997), 2004-03, Vol.27 (2), p.124

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

Quantification of circulating endothelial cells by flow cytometry

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors

Suchergebnisse filtern